Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies — with special reference to the combination of PLAP and CA54/61 assay

Nozawa, Shiro; Udagawa, Yasuhiro; Ohkura, H; Negishi, Y; Akiya, K; Inaba, Noriyuki; Takamizawa, H; Kimura, Eizo; Terashima, Y

doi:10.1016/0009-8981(90)90045-t

Cited by 15 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in accordance with other reports [26,27,33], while De Broe ct al. [25] concluded that CA125 and PLAP may behave as indepen dent markers in patients with ovarian malig nancies.…”

Section: Discussionsupporting

confidence: 83%

“…In recent reports, in assays using mono clonal antibodies, raised serum concentra tions of PLAP have been found in about 35-50% of the patients with ovarian cancer [19,[25][26][27][28]]. In the current report, elevation of PLAP-C2 levels was observed in 43% of the patients with evidence of disease at the time of sampling.…”

Section: Discussionsupporting

confidence: 53%

“…However, the PLAP-C2 assay did not add significantly to 172 Vcrgote/Abelcr/Bormer/Stigbrand/ Tropé/Nustad PI.AP-C2 and CA125 in Ovarian Cancer the predictive value of CA125 in the diagnosis and follow-up of epithelial ovarian cancer. The role of PLAP-like enzyme in the clinical management of nonepithelial ovarian cancer, especially dysgerminoma [15,20,25,26], re mains to be established.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

CA125 and Placental Alkaline Phosphatase as Serum Tumor Markers in Epithelial Ovarian Carcinoma

Vergote¹,

Abeler²,

Børmer³

et al. 1992

Tumor Biol

View full text Add to dashboard Cite

Placental alkaline phosphatase (PLAP) was measured by an immunoradiometric assay using the monoclonal antibody C2 (PLAP-C2). Serum samples of 135 patients with epithelial ovarian cancer were analyzed, and the results were compared with CA125 levels. CA125 and PLAP-C2 were elevated in 85 and 43% of the patients, respectively. Only 1 patient with normal CA125 and evidence of disease at the time of sampling had an elevated PLAP-C2. Fifty-three patients with measurable tumor were followed longitudinally during chemotherapy. Correct correlation with disease evolution was observed in 95% of the patients for CA125 and in 59% for PLAP-C2. The PLAP-C2 assay did not add significantly to the predictive value of CA125 in the diagnosis and follow-up of epithelial ovarian cancer.

show abstract

“…This is in accordance with other reports [26,27,33], while De Broe ct al. [25] concluded that CA125 and PLAP may behave as indepen dent markers in patients with ovarian malig nancies.…”

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CA125 and Placental Alkaline Phosphatase as Serum Tumor Markers in Epithelial Ovarian Carcinoma

Vergote¹,

Abeler²,

Børmer³

et al. 1992

Tumor Biol

View full text Add to dashboard Cite

show abstract

“…In our study group, the mean pre-op level of HSF was 14+11.4 U/L which showed significant difference (13) reported high level in 60% of patients of serous cystadenocarcinoma of ovary and also reported that none of the healthy women studied were PLAP positive. Elevated levels of HSF have been reported by a number of other investigators in 30-60% of ovarian carcinoma (14,4).…”

Section: Resultsmentioning

confidence: 42%

Role of heat stable fraction of alkaline phosphatase as an adjunct to ca 125 in monitoring patients of epithelial ovarian carcinoma

Nigam

Jain

Goyal

et al. 2005

Indian J Clin Biochem

View full text Add to dashboard Cite

Heat stable fraction (HSF) of alkaline phosphatase (ALP) was evaluated as an adjunct to CA 125 as a tumour marker for epithelial ovarian cancer in a follow-up study. In our study group 63.4% of patients had elevated HSF levels (≥10U/L) and 93.3% had elevated CA 125 levels (>35U/mL). The sensitivity of CA 125 and HSF was 93.3% and 63.3% respectively. The decline in the activity of HSF, over the pre-op levels was highly significant after the first (p=0.001) chemotherapy cycle and significant after the second and third cycles (p<0.029). Thereafter, HSF activity was almost undetectable. The decrease in CA 125 levels over the pre-op levels was significant after the first, second, third (p<0.001) and fourth (p<0.034) chemotherapy cycle. HSF can be used alone or as an adjunct to CA 125 in screening and monitoring patients of ovarian carcinoma especially in remote areas where sophisticated facilities are not available and in patients in which CA 125 levels are not raised preoperatively.

show abstract

“…Epenetos et al [36] and Critchley et al [37] have had success in targeting PLAP-producing cancers in patients by employing radioactively-labeled monoclonal antibodies. They and others have reason to believe that therapeutic agents can be delivered to the tumor targets by this mechanism [36,[38][39][40][41][42][43][44], Clinical studies have made use of tumor marker alkaline phosphatase isoenzymes -GCAP as a specific marker of germ cell tu mors [45][46][47][48][49], IAP, a marker of hepatoma [50][51][52] and PLAP, a more general tumor marker [33,[53][54][55].…”

Section: Clinical Studiesmentioning

confidence: 99%

Isozymes, Tumor Markers and Oncodevelopmental Biology

Fishman

1995

Tumor Biol

View full text Add to dashboard Cite

This is the history of discoveries of several enzyme tumor markers in the awardees laboratory. The first, β-glucuronidase, was originally related to the physiological actions of estrogens and androgens. Perfection of histo-chemical techniques based on new substrates demonstrated the dual localization of β-glucuronidase in endoplasmic reticulum and lysosomes. Tumor tissues, in general, are enriched with β-glucuronidase. Next, acid phosphatase of the prostate gland possesses the distinctive property of undergoing inhibition by L-tartrate. This organ-specific inhibitor was incorporated into the Fishman-Lerner method for measuring serum acid phosphatase of prostatic origin. This significantly increased the specificity of the measurement of serum acid phosphatase for prostatic cancer. Finally, the discovery of the Regan Isoenzyme, placental alkaline phosphatase (PLAP) in a patient with disseminated lung cancer provided a tumor marker useful in the management of gonadal tumors, in particular. Closely related to PLAP is germ cell alkaline phosphatase which is eutopically expressed in seminoma. Finally, radioimmunolocalization and radioimmunotherapy of PLAP in these tumors have been achieved by others.

show abstract

Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies — with special reference to the combination of PLAP and CA54/61 assay

Cited by 15 publications

References 7 publications

CA125 and Placental Alkaline Phosphatase as Serum Tumor Markers in Epithelial Ovarian Carcinoma

CA125 and Placental Alkaline Phosphatase as Serum Tumor Markers in Epithelial Ovarian Carcinoma

Role of heat stable fraction of alkaline phosphatase as an adjunct to ca 125 in monitoring patients of epithelial ovarian carcinoma

Isozymes, Tumor Markers and Oncodevelopmental Biology

Contact Info

Product

Resources

About